Skip to main content
SpringerLink
Log in

Is Total Body Irradiation Necessary in Bone Marrow Transplantation for Pediatric ALL?

  • Chapter
Current Controversies in Bone Marrow Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

  • 98 Accesses

Abstract

Allogenic bone marrow transplantation (allo-BMT) for nonmalignant disease requires ablation of the immune system to permit hematopoietic and lymphoid engraftment unless the donor is syngeneic or the recipient is profoundly immunoincompetent. When BMT is performed for malignant disease, treatment of the recipient to permit engraftment is also used to eliminate residual malignancy. The ultimate success of allo-BMT for leukemia clearly depends upon immunomodulation and graft vs tumor effect in addition to the direct antileukemic effect of the preparative regimen. Nonetheless, the importance of an effective preparative regimen is crucial. Optimal regimens remain a topic of uncertainty in transplantation for acute leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, and Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man, J. Clin. Invest., 38 (1959) 1709–1716.

    Article  PubMed  CAS  Google Scholar 

  2. Santos GW, Sensenbrenner LL, Burke PJ,Marrow transplantation in man following cyclophosphamide, Transplant. Proc., 3 (1971) 400–404.

    PubMed  CAS  Google Scholar 

  3. Buckner CD, Clift RA, Fefer A,Marrow transplantation for the treatment of acute leukemia using HLA-identical siblings, Transplant. Proc., 6 (1974) 365–366.

    PubMed  CAS  Google Scholar 

  4. Gilson D and Taylor RE. Total body irradiation: report on a meeting organized by the BIR oncology committee, Br. J. Radiol., 70 (1997) 1201–1203.

    PubMed  CAS  Google Scholar 

  5. Dutreix J, Girinski T, Cosset JM,Blood cell kinetics and total body irradiation, Radiother. Oncol., 9 (1987) 119–129.

    Article  PubMed  CAS  Google Scholar 

  6. Shank B. Radiotherapeutic principles of bone marrow transplantation. In Forman SJ, Blume KJ, Thomas ED (eds.), Bone Marrow Transplantation, Blackwell, Boston, (1995), pp. 96–113.

    Google Scholar 

  7. Burnett AK, Robertson AG, Hann IMIn vitro T-depletion of allogeneic bone marrow: prevention of rejection in HLA-matched transplants by increased TBI, Bone Marrow Transplant., 1 (Suppl 1) (1986) 121.

    Google Scholar 

  8. Casper J, Camitta B, Truitt RUnrelated bone marrow donor transplants for children with leukemia or myelodysplasia, Blood, 85 (1995) 2354–2363.

    PubMed  CAS  Google Scholar 

  9. Wheldon TE. Radiobiological basis of total body irradiation, Int. J. Radiat. Oncol. Biol. Phys., 70 (1997) 1204–1207.

    CAS  Google Scholar 

  10. Uckun FM, Chandan-Langlie M, Jaszcz WRadiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia, Cancer Res., 53 (1993) 1431–1436.

    PubMed  CAS  Google Scholar 

  11. Gordon BG Warkentin PL, Strandjord SEAllogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation, Bone Marrow Transplant.,20 (1997) 5–10.

    Google Scholar 

  12. Chou RH Wong GB Kramer JHToxicities of total body irradiation for pediatric bone marrow transplantation, Int. J. Radiat. Oncol. Biol. Phys.,34 (1996) 843–851.

    Google Scholar 

  13. Deeg HJ. Acute and delayed toxicities of total body irradiation, Int. J. Radiat. Oncol. Biol. Phys., 9 (1983) 1933–1939.

    Article  PubMed  CAS  Google Scholar 

  14. Demierer T, Petersen FB, Appelbaum FR,Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a phase I/II trial, Int. J. Radiat. Oncol. Biol. Phys., 32 (1995) 1103–1109.

    Article  Google Scholar 

  15. Belkacemi Y, Pene F, Touboul ETotal body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission, Strahlenther Onkol. 174 (1998) 92–104.

    Article  PubMed  CAS  Google Scholar 

  16. Gore EM, Lawton CA, Ash RCPulmonary function changes in long-term survivors of bone marrow transplantation, Int. J. Radiat. Oncol. Biol. Phys., 36 (1996) 67–75.

    Article  PubMed  CAS  Google Scholar 

  17. Bradley J, Rett C, Goldman SHigh energy total body irradiation as preparation for bone marrow transplantation in leukemia patients: treatment technique and related complications, J. Pediatr., 40 (1998) 391–396.

    CAS  Google Scholar 

  18. Nysom K, Holm K, Hesse BLung function after allogeneic bone marrow transplantation for leukemia or lymphoma, J. Pediatr., 74 (1996) 432–436.

    CAS  Google Scholar 

  19. Huma Z, Boulad F, Black PGrowth in children after bone marrow transplantation for acute leukemia, Blood, 86 (1995) 819–824.

    PubMed  CAS  Google Scholar 

  20. Sanders JEEndocrine problems in children after bone marrow transplant for hematologic malignancies, Bone Marrow Transplant., 8 (1991) 2–4.

    PubMed  Google Scholar 

  21. Holm K, Nysom K, Rasmussen MHGrowth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency, Bone Marrow Transplant., 18 (1996) 163–170.

    PubMed  CAS  Google Scholar 

  22. Clement-DeBoers A, Oostdijk W, Van Weel-Sipman MHFinal height and hormonal function after bone marrow transplantation in children, J. Pediatr., 129 (1996) 544–550.

    Article  CAS  Google Scholar 

  23. Alter CA, Thornton PS, Willi SMGrowth in children after bone marrow transplantation for acute myelogenous leukemia as compared to acute lymphocytic leukemia, J. Ped. Endocrinol. Metabol., 9 (1996) 51–57.

    Article  CAS  Google Scholar 

  24. Sarafoglov K, Bouvlad F, Gillio AGonadal function after bone marrow transplantation for acute leukemia during childhood, J. Pediatr., 130 (1997) 210–216.

    Article  Google Scholar 

  25. Cool VA. Long-term neuropsychological risks in pediatric bone marrow transplant: what do we know? Bone Marrow Transplant., 18 (1996) 545–549.

    Google Scholar 

  26. Curtis RE, Rawlings PA, Deeg HJSolid cancers after bone marrow transplantation, N. Engl. J. Med., 336 (1997) 897–904.

    Article  PubMed  CAS  Google Scholar 

  27. Neglia JP, Meadows AT, Robison LLSecond neoplasms after acute lymphoblastic leukemia in childhood, N. Engl. J. Med., 325 (1991) 1330–1336.

    Article  PubMed  CAS  Google Scholar 

  28. Kubuta M, Akiyama Y, Koishi SSecond malignancy following treatment of acute lymphoblastic leukemia in children, Int. J. Hematol., 57 (1998) 397–401.

    Article  Google Scholar 

  29. Santos GW, Tutschka PJ, Brookmeyer R,Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide, N. Engl. J. Med., 309 (1983) 1347–1352.

    Article  PubMed  CAS  Google Scholar 

  30. Klein J, Avalos B, Belt PBone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy, Bone Marrow Transplant., 17 (1997) 479–483.

    Google Scholar 

  31. Ratanatharathom V, Uberti JP, Sensenbrenner LLPreparative regimens without total body irradiation in the recipients of unrelated donor marrow, Blood, (1994) 342a.

    Google Scholar 

  32. Ramirez M, Diaz MA, Garcia-Sanchez FChimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia, Bone Marrow Transplant.,18 (1996) 11611165.

    Google Scholar 

  33. Slattery JD and Risler JL. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation, Therapeut. Drug Monitor, 20 (1998) 543–549.

    Article  CAS  Google Scholar 

  34. Vassal G, Koscielny S, Challine DBusulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation, Cancer Chemother. Pharmacol., 37 (1996) 247–253.

    Article  PubMed  CAS  Google Scholar 

  35. Schuler US, Ehrsam M, Schneider APharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation, Bone Marrow Transplant., 20 (1998) 241–244.

    Article  Google Scholar 

  36. Morgan M, Dodds A, Atkinson KThe toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation, Br. J. Hematol., 77 (1991) 529–534.

    Article  CAS  Google Scholar 

  37. Ringden O, Labopin M, Tura SA comparison of busulfan versus total body irradiation combined with cyclopshosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia, Br. J. Hematol., 93 (1996) 637–645.

    Article  CAS  Google Scholar 

  38. Davies SM, Ramsay NK, Klein JPComparison of preparative regimens in transplants for children with acute lymphoblastic leukemia, submitted for publication.

    Google Scholar 

  39. Ringden O, Remberger M, Ruutu TIncreased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogenic marrow recipients with leukemia, Blood, 93 (1999) 2196–2201.

    PubMed  CAS  Google Scholar 

  40. Brochstein J, Keman N, Groshen SAllogeneic bone marrow transplantation after hyperfractionated total body irradiation and cychophosphamide in children with acute leukemia, N. Engl. J. Med., 217 (1977) 1618–1624.

    Google Scholar 

  41. Coccia P, Strandjord S, Warkentin PHigh-dose cytosine arabinoside and fractionated total body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission, Blood, 71 (1988) 888–893.

    PubMed  CAS  Google Scholar 

  42. Deconinck E, Cahn JY, Milpied NAllogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI high-dose Ara-C and melphalan), Bone Marrow Transplant.,20 (1997) 731735.

    Google Scholar 

  43. Moussalem M, Esperov Bovrdeau H, Devergie AAllogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival relapse and graft versus host disease, Bone Marrow Transplant., 15 (1995) 943–947.

    PubMed  CAS  Google Scholar 

  44. Von Bueltzingloeuen A, Esperov-Bourdeau H, Souillet GAllogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a cooperative study of the societe Francaise de Greffede Moelle, Bone Marrow Transplant., 16 (1995) 521–527.

    Google Scholar 

  45. Favre C, Nardi M, Dini GThe role of total body irradiation (TBI). The Italian Association of Pediatric Hematology (AIEOP) BMT Study Group, Bone Marrow Transplant.,18(Suppl 2) (1996) 71–74.

    Google Scholar 

  46. Ruutu T, Remberger MA randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group, Blood,83 (1994) 2723–2730.

    Google Scholar 

  47. Feig SA, Harris RE, and Sather HN. Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: a study of the Children’s Cancer Group (CCG-1884), Med. Pediatr. Oncol., 29 (1997) 534–540.

    Google Scholar 

Download references

Authors
  1. Susan R. Wiersma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan B. Shurin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Brian J. Bolwell MD (Director, Staff Physician) (Director, Staff Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Wiersma, S.R., Shurin, S.B. (2000). Is Total Body Irradiation Necessary in Bone Marrow Transplantation for Pediatric ALL?. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-657-7_5

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9812-7

  • Online ISBN: 978-1-59259-657-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation